Aromatherapy for the treatment of PONV in children: a pilot RCT

Mathew B. Kiberd 1*, Suzanne K. Clarke 1, Jill Chorney 1,2,3, Brandon d'Eon 1 and Stuart Wright 1,4

Abstract

Background: Postoperative nausea and vomiting (PONV) is one of the most common postoperative complications of general anesthesia in pediatrics. Aromatherapy has been shown to be effective in treating PONV in adults. Given the encouraging results of the adult studies, we planned to determine feasibility of doing a large-scale study in the pediatric population.

Methods: Our group conducted a pilot randomized controlled trial examining the effect of aromatherapy on postoperative nausea and vomiting in patients 4-16 undergoing ambulatory surgery at a single center. Nausea was defined as a score of 4/10 on the Baxter Retching Faces Scale (BARF scale). A clinically significant reduction was defined as a two-point reduction in Nausea. Post operatively children were administered the BARF scale in 15 min internals until discharge home or until nausea score of 4/10 or greater. Children with nausea were randomized to saline placebo group or aromatherapy QueaseEase™ (Soothing Scents, Inc, Enterprise, AL: blend of ginger, lavender, mint and spearmint). Nausea scores were recorded post intervention.

Results: A total of 162 subjects were screened for inclusion in the study. Randomization occurred in 41 subjects of which 39 were included in the final analysis. For the primary outcome, 14/18 (78 %) of controls reached primary outcome compared to 19/21 (90 %) in the aromatherapy group (p = 0.39, Eta 0.175). Other outcomes included use of antiemetic in PACU (control 44 %, aromatherapy 52 %, p = 0.08), emesis (Control 11 %, 9 % aromatherapy, p = 0.87, Eta = 0.03). There was a statistically significant difference in whether subjects continued to use the intervention (control 28 %, aromatherapy 66 %, p-value 0.048, Eta 0.33).

Conclusion: Aromatherapy had a small non-significant effect size in treating postoperative nausea and vomiting compared with control. A large-scale randomized control trial would not be feasible at our institution and would be of doubtful utility.

Trial registration: ClinicalTrials.gov NCT02663154.

Keywords: MeSH postoperative nausea and vomiting, Aromatherapy, Ambulatory surgical procedures, Pediatrics, Nausea, Antiemetics, Complementary therapies
of isopropyl alcohol compared with standard treatment for relief of nausea. [8] Peppermint was also examined in this Cochrane review and there was insufficient quality evidence to show an effect of peppermint-based aromatherapy. However, this review did not include the largest trial in adult aromatherapy for PONV. In 2013 Hunt et al. enrolled 1151 adults in a four armed randomized control trial for aromatherapy and showed that the blend (ginger, peppermint, spearmint and cardamom) reduced nausea compared to saline: 82.4 % reported reduced nausea with blend compared to control 39.7 % (P < 0.001) [6]. A number of smaller studies have also shown efficacy of aromatherapy in treating adult PONV [5, 7, 9].

QueaseEase™ (Soothing Scents, Inc, Enterprise, AL) is one of the proprietary blends of aromatherapy that has been shown to be effective in treating PONV in adults. In a study of 339 patients, 94 reported nausea and were randomized to aromatherapy or placebo. The intervention resulted in a reduction in mean visual analogue nausea score of 5.4 pre aromatherapy to 3.4 post aromatherapy p = 0.01. This difference was significantly greater than nausea reduction by placebo: 5.6 pre and 4.4 post P = 0.03 [5]. Given the encouraging results of the first adequately powered adult study, we planned to determine feasibility of doing a large-scale study in the pediatric population.

Herein we report a pilot randomized control trial to assess the feasibility of a larger scale randomized clinical trial. The aim is to identify refinements necessary to the study protocol, assess costs, and obtain a valid estimate for power calculations. Hence, to answer in future studies whether aromatherapy is an effective therapy for the management of PONV in the pediatric population.

Methods
The study was conducted at the Isaac Walton Killam (IWK) Health Centre in Halifax, Nova Scotia. After institutional ethics review, participants were recruited in two discrete collection periods by three research assistants (July 14-Sept 23 2014 and March 24-May 19 2015). Inclusion criteria included children aged 4–16, Anesthesia Society of America Physical Status I or II (ASA I or II), absence of neurodevelopmental disorders, and undergoing elective day surgery. Exclusion criteria included patient or family refusal, allergy or sensitivity to aromatherapy components, inability to smell or failure to meet the inclusion criteria. Of note, the protocol was modified at the study mid-point to increase enrollment. Originally, only otolaryngology and ophthalmology patients were included, but this was expanded to the previously described inclusion criteria due to low rates of PONV.

Study intervention
The intervention was a proprietary blend of aromatherapy essential oils (QueaseEASE™). The mixture included (Lavandula angustifolia, Mentha Spicata, Mentha xipiperita and Zingiber officinale) in equal proportions and is registered with Health Canada (Natural Product Number 80036451). The control was with identical housing but contained only saline (Fig. 1).

Measurement tool
BARF scale
The Baxter Retching Faces (BARF) scale is a pictorial nausea scale of 0–10 with 6 faces. This tool was validated in the paediatric emergency room, with paediatric cancer inpatients and in the paediatric postoperative care unit [10]. This instrument has achieved construct validity for assessment of severity of paediatric nausea. The scale also has convergent and discriminatory validity and can detect changes after therapy. Originally validated for patients aged 7–18 years old, this scale has been used in ages as low as 4 [10].

Procedure
A pilot trial designed to accurately replicate future larger study design was undertaken as follows.

On the day of their surgical procedure, children were screened using the inclusion and exclusion criteria. Children whom met the criteria were enrolled after obtaining informed consent from the parent with assent from the child. Enrolment took place prior to the start of the scheduled procedure.

Upon enrollment, charts were reviewed for demographic data (age, sex, weight), co-morbidities, previous anesthetics, and previous PONV. Attending anesthesiologists were not made aware of the subject's participation in the study and there were no attempts made to alter standard anesthetic management. Not standardizing anesthesia management improves external validity and applicability to the general pediatric peri-operative population.

Post-operatively subjects went to the first stage post-anesthetic care unit (PACU 1) until they met discharge criteria. They were then moved to PACU 2 (post recovery) until discharge home. Upon arrival to PACU 1, the research assistant assessed for nausea using the BARF scale at 15-min intervals or if the patient or nurse reported nausea. The nurse also independently assessed nausea at 15-min intervals. If the patient reported a BARF scale of 4 or greater they were randomized to the intervention aromatherapy or a saline inhaler. Randomization was by block 6 design. Concealment was maintained by using sequentially numbered opaque envelopes containing the identical appearing intervention and control inhalers (Fig. 1). Upon the report of nausea, the patient was given the inhaler with instructions on its use. Specifically, subjects were asked to take deep regular breaths through their nose with the inhaler in front of their nose. They were told to do so as long as they wanted and to repeat as necessary until the
nausea passed. Based on the preference of the participant, the inhaler was held by either the participant, a parent, or the research assistant. BARF scale was re-evaluated after sufficient exposure (defined as 5 respiratory cycles of nasal breathing using the inhaler within 30 cm from their nares). The primary outcome was defined as a 2-point reduction in the BARF-Scale. A two-point difference is a one-face difference on the pictorial scale. This difference would be analogous to a significant clinical effect in the pain literature and has been used in the pediatric nausea literature [10]. Additional BARF scale measurements were collected at 15-min intervals until the time of discharge.

Statistical analysis

Power consideration
The nature of this study was to select a convenience sample of 40 patients (20 in each group) to serve as an estimate for power in a future study. The current literature does not contain a study similar enough that assumptions for a sample size calculation would be valid. A sample size of 40 patients is generally sufficient to create an accurate estimate of variance in which a future power calculation could be made.

Analysis
SPSS version 23.0 was used for analysis. Descriptive statistics were generated and are presented as means with standard deviation or as percentages. T-tests and chi-square were used to compare groups on baseline data including child age, surgical procedure, previous PONV and co-morbidities. T-tests (or Analysis of Covariance) were used to examine differences on primary.

Results
A total of 162 subjects were screened for inclusion in the study. Of these subjects, 4 surgeries were cancelled, 2 were changed to same day admission, 2 parents withdrew consent, and 2 patients were excluded retrospectively for ASA status III. The overall rate of nausea as defined as 4/10 on the BARF nausea scale was 41/152 (27%). Randomization occurred in 41 subjects of which 2 were excluded post randomization (1 subject in each arm [1], for failure to meet exposure criteria and [1] for leaving before assessment (Fig. 2)).

Age, sex, ASA status, total time in operating room, PONV prophylaxis and pain management were not significantly different between intervention and control groups (Table 1). There were differences in the type of surgical procedures between groups. The major difference was a greater portion of patients in the aromatherapy group had ENT procedures compared with the control group (81% versus 44%) (Table 1). When comparing the groups for nausea prophylaxis, 78% of the control and 94% of the aromatherapy group received Ondansetron and 94% of control and 86% of the aromatherapy group received dexamethasone. The groups were also compared for multimodal analgesia, including acetaminophen: 94% of controls and 95% of aromatherapy subjects received multimodal analgesia.

For the primary outcome, 14/18 (78%) of controls reached the cutoff of a 2-point reduction on the BARF scale compared to 19/21 (90%) in the aromatherapy group (p = 0.39, Eta 0.175) (Table 2). Other outcomes included use of antiemetic in PACU (control 44%, aromatherapy 52%; P = 0.75, Eta 0.08), emesis (Control 11%, 9% aromatherapy; P = 0.87, Eta = 0.03) and reduction in BARF scale magnitude at 15-min post intervention [control 3.8 (95% CI ±3.7), aromatherapy 3.2 (95% CI ±2.4), p-value = 0.52, Eta = 0.01)] (Table 2). There was a statistically significant difference in whether subjects continued to use the intervention (control 28%, aromatherapy 66%, p-value 0.048, Eta 0.33) (Table 2). Subjects were considered to have continued the intervention if they used the intervention beyond the first 15 min.
Study feasibility indicators
There were 46 study days over a period of 6 months resulting in 3.2 subjects recruited per study day and a randomization rate of 0.9 subjects per day. Approximate cost of the study was $8 000 mainly from research assistant salary and to a small extent, materials. Thus, a cost of $205 for each randomized subject.

Discussion
The primary goal of the current study was to assess the feasibility of a larger trial of aromatherapy for PONV in children. The primary outcome of 2-point reduction in the BARF scale was a surrogate for moderate PONV. The outcome had only a small-modest effect size (control 78 %, aromatherapy 90 %, Eta = 0.175). In order to be powered to a significance level ($\alpha$) of 0.05 and power of 0.8, the sample size would need to be approximately 514 per group (making no adjustments for attrition) using the effect size of the primary outcome. Alternatively using the incidence of nausea the sample size would be 190 patients per group. Given the recruitment rates of the study the lowest estimate of number children we would need to screen is 1 200. Concrete, less subjective outcomes such as pharmacological intervention or emesis would require even larger sample sizes to find any difference as evidenced by the low effect sizes found in this study (0.08 and 0.03 respectively).

Nausea rates at our center (27 %) were close, though somewhat lower, to literature values [2, 6]. Compliance with recommendations for PONV prophylaxis are consistent with recommendations from major society guidelines [1]. Most children in this study received both Ondansetron (74 %) and dexamethasone (95 %) as intraoperative prophylaxis. Multimodal analgesia was utilized in most patients to reduce narcotic use (95 %). The widespread use of multi-modal analgesia and PONV prophylaxis in our center likely has resulted in our lower rates of nausea.
Limitations of the study include low planned sample size, as this was a pilot study. Unreliability of the outcome measurement (BARF scale) in the youngest children may also contribute to error. Although the BARF scale has been validated down to 4 years old, there is variability in children's ability to self-report on internal experiences in this age group that may have influenced their use of this scale [11]. Despite randomization there was a difference in the types of surgeries patients in each group received. For example, more patients in the control group had Ophthalmological surgery compared with aromatherapy (28% versus 5%). This was likely balanced by a higher portion of aromatherapy patient's having ENT surgery. Initial nausea scores were not different between the two groups. In future study stratification by surgery may be necessary. Furthermore, the primary outcome measurement is an indirect surrogate rather than a concrete outcome. As PONV can occur for a period spanning longer than the time patients spend in day surgery, this study would not account for any PONV experienced, and possibly prevented by the intervention, en route home or over the first 24 h. Modifiable limitations include better concealment. Despite a delivery system with controlled exposure to the therapy (twist top) the aroma rapidly penetrated the area around the patient. Researchers and nurses correctly identified intervention versus control in all cases. In future studies nose plugs could be considered.

Future directions may include an adequately powered study with more attention to concealment and the inclusion of less subjective outcomes (reduction in emesis, and reduction in rescue anti-nausea medications). However, given the small effect size, the value is dubious. Other areas to consider exploring are the effects of aromatherapy on PONV, comfort, anxiety and pain in the extended post-operative period (i.e., over the following 24–48 h). Subjects in the aromatherapy group were more likely to continue using the intervention compared to the control group (66% versus 28%, p-value 0.048, Eta 0.33). This may suggest that the aromatherapy could be having another unmeasured effect on patient comfort. This effect may be a reduction in anxiety. In future studies this should be explored further (measures of pain, comfort or anxiety reduction for example).

**Conclusion**

This pilot study revealed methodological flaws that need to be corrected before embarking on a larger randomized control study. A larger trial would likely need to take place at a larger center or be multi-center in order to speed recruitment.

### Table 1
Summary of demographic data between control and aromatherapy arm

|                          | Control            | Aromatherapy        |
|--------------------------|--------------------|---------------------|
| Age (YEAR)               | 8.5 (95 % CI ±3.4) | 6.9 (95 % CI ±3.1)  |
| Sex (%male)              | 9/18 (50 %)        | 12/21 (57.1 %)      |
| ASA (I or II)            | 100 %              | 100 %               |
| Surgery                  |                    |                     |
| ENT                      | 8/18 44 %          | 17/21 81 %          |
| Ophthalmology            | 5/18 27.8 %        | 1/21 4.8 %          |
| Plastic surgery          | 2/18 11.1 %        | 0/21 0 %            |
| Orthopaedics             | 0/18 0 %           | 0/21 0 %            |
| Dental                   | 1/18 5.6 %         | 3/21 14.3 %         |
| Urology                  | 0/18 0 %           | 0/21 0 %            |
| General surgery          | 2/18 11.1 %        | 0/21 0 %            |
| OR time (minutes)        | 66 (95 % CI ±18)   | 64 (95 % CI ±34)    |

PONV Prophylaxis

|                          | Control            | Aromatherapy        |
|--------------------------|--------------------|---------------------|
| TIVA                     | 4/18 22 %          | 4/21 19 %           |
| Ondansetron              | 14/18 77.8 %       | 15/21 71 %          |
| Dexamethasone            | 17/18 94.4 %       | 18/21 85.7 %        |

Pain management

|                          | Control            | Aromatherapy        |
|--------------------------|--------------------|---------------------|
| Acetaminophen            | 17/18 94.4 %       | 20/21 95.2 %        |
| Ketorolac                | 6/18 33 %          | 2/21 9.5 %          |
| Morphine dose (mg/kg)    | 0.14 (95 % CI ±0.1)| 0.13 (95 % CI ±0.09)|

Continuous data were expressed as mean and 95 % CI. Otherwise data expressed as percentage of subjects meeting outcome.

### Table 2
Summary of primary and secondary outcomes

|                          | Control            | Aromatherapy        | p-value | Effect (Eta) |
|--------------------------|--------------------|---------------------|---------|--------------|
| 2 point reduction on BARF scale (Y/N) | 14/18 (77.8 %) | 19/21 (90.5 %) | 0.39 | 0.175 |
| Use of pharmacological rescue (Y/N) | 8/18 (44.4 %) | 11/21 (52.4) | 0.75 | 0.079 |
| Emesis (Y/N)             | 2/18 (11.1 %)      | 2/21 (9.5 %)       | 0.87    | 0.026 |
| Continued use of intervention (Y/N) | 5/18 (28 %) | 14/21 (66 %) | 0.0048 | 0.33 |
| Reduction in BARF scale magnitude | 3.8 (95 % CI ±3.7) | 3.2 (95 % CI ±2.4) | 0.52 | 0.01 |

Reduction in BARF magnitude is expressed as mean and 95 % CI. The means were compared using T-Test with calculation of effect size. Otherwise data are expressed as percentage of subjects meeting the outcome (binary Y/N) and means were compared using Chi-Square test with calculation of effect size.
Informed consent was obtained from the patient's parent or guardian. When a parent or guardian provided informed consent, patient assent was also obtained. When consent for raw data sharing was not obtained in our ethics review process. Data can be made available through the corresponding author if approved by our ethics review board at the IWK on a case-by-case basis.

Acknowledgements
The authors would also like to thank the PACU staff and nurses for their ongoing dedication to research and patient care.

Funding
Funding of this study was from the Dr Thomas Coonan Studentship through the Dalhousie Medical Research Foundation. The Dalhousie Medical Research Foundation did not contribute to design, execution or interpretation of data.

Availability of data and materials
Data are not available, as consent for raw data sharing was not obtained in our ethics review process. Data can be made available through the corresponding author if approved by our ethics review board at the IWK on a case-by-case basis.

Authors' contributions
MK: Experimental design (protocol), data collection, manuscript writing and approval of final draft. SC: Experimental design, ethics submission, data collection, manuscript writing and approval of final draft. JC: Ethics submission, manuscript writing and approval of final draft. BD: Manuscript collection, manuscript writing and approval of final draft. SW: Experimental design, ethics submission, manuscript writing and approval of final draft.

Competing interests
The aromatherapy sticks and saline control were provided in kind by QueaseEASE™. The company was not involved in study methodology or dissemination. The authors otherwise have no disclosures.

Ethics approval and consent to participate
The research protocol was approved before enrollment by the ethics review committee at the IWK health sciences center. Ethics approval ID: 1016941. Informed consent was obtained from the patient’s parent or guardian. When a parent or guardian provided informed consent, patient assent was also obtained.

Author details
1. Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, 1276 South Park Street, 231-C 10 West Victoria Building, Halifax, NS B3J 2Y9, Canada. 2. Department of Psychology and Neuroscience, Dalhousie University, Halifax, NS, Canada. 3. Center for Pediatric Pain Research, IWK Health Centre, Halifax, NS, Canada. 4. Department of Pediatric Anesthesia, IWK Health Sciences Center, IWK Pediatric Anesthesia and Complex Pain Team, 5850/5989 University Ave, Halifax, NS B3K 6R8, Canada.

Received: 14 June 2016 Accepted: 24 October 2016
Published online: 09 November 2016

References
1. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85–113.
2. Heyland K, Dangel P, Gerber AC. Postoperative nausea and vomiting (PONV) in children. Eur J Pediatr Surg. 1997;7:230–3.
3. Hill RP, Lubarsky DA, Phillips-Bute B, Fortney JT, Creed MR, Glass PS, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology. 2000;92(4):958–67.
4. Diez L. Assessing the willingness of parents to pay for reducing postoperative emesis in children. Pharmacoeconomics. 1998;13:589–95.
5. Hodge NS, McCarthy MS, Pierce RM. A prospective randomized study of the effectiveness of aromatherapy for relief of postoperative nausea and vomiting. J Perianesth Nurs. 2014;29(1):15–11. Elsevier Ltd.
6. Hunt R, Diememann J, Norton HJ, Hartley W, Huddgens A, Stem T, et al. Aromatherapy as treatment for postoperative nausea: A randomized trial. Anesth Analg. 2013;117(3):597–604.
7. Sites DS, Johnson NT, Miller JA, Torbush PH, Hardin JS, Knowles SS, et al. Controlled breathing with or without peppermint aromatherapy for postoperative nausea and/or vomiting symptom relief: A randomized controlled trial. J Perianesthesia Nurs. 2014;29(1):12–9. Elsevier Ltd.
8. Hines S, Steels E, Chang A, Gibbons K. Aromatherapy for treatment of postoperative nausea and vomiting. Cochrane Database Syst Rev. 2012;4:CD007598.
9. Madum S, Chaharsoughi NT, Banisheshem A, Vashani HB. The effect of massage therapy on chemotherapy-induced nausea and vomiting in pediatric cancer. Iran J Nurs Midwifery Res. 2013;18(4):280-4.
10. Baxter AL, Watcha MF, Baxter WW, Leong T, Wyatt MM. Development and validation of a pictorial nausea rating scale for children. Pediatrics. 2011;127:e1542–9.
11. Von Baeyer CL, Uman LS, Chambers CT, Gouthro A. Can we screen young children for their ability to provide accurate self-reports of pain? Pain [Internet]. Int Assoc Stud Pain. 2011;152(6):1327–33.